Dyadic to Present at the Roth Capital Partners 2006 New York Conference on September 7, 2006 at 12:00 p.m. EDT; Webcast Will Be
31 Août 2006 - 10:11PM
Business Wire
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that its President and Chief Executive Officer,
Mark Emalfarb, will make a presentation at the Roth Capital
Partners 2006 New York Conference to be held at the Westin New York
at Times Square on September 6-7, 2006. Mr. Emalfarb's presentation
is scheduled for September 7 at 12:00 p.m. EDT. A simultaneous
webcast of the presentation may be accessed by clicking the webcast
link at http://www.dyadic.com. A replay will be available for 30
days at the same internet address. Mr. Emalfarb plans to discuss
the Company's progress in the development of its technologies for
the production of new, better and more affordable products in its
three core business areas: -- Biorefineries, to communicate the
Company's recent advances in the development of its patented and
proprietary enzyme mixtures to make abundant low cost sugars from
agricultural plant materials (energy crops). Sugars are currently
being used to produce ethanol, plastics and polymers to displace
petroleum in a variety of manufacturing and refining processes. --
Biosciences, to provide an update on the Company's progress to
leverage its C1 Host Technology for use in collaboration with
biotech and pharmaceutical companies to enable them to more
efficiently discover, develop and produce new, better and more
affordable human antibodies and other drugs; and -- Enzymes, to
report on the Company's progress in expanding from its historical
textile enzyme business to larger and more profitable markets such
as pulp and paper and animal feed. About Dyadic Dyadic
International, Inc., based in Jupiter, Florida, with operations in
the United States of America, Hong Kong and mainland China, Poland
and The Netherlands, is engaged in the development, manufacture and
sale of biological products using a number of proprietary fungal
strains to produce enzymes and other biomaterials, principally
focused on a system for protein production based on the patented
Chrysosporium lucknowense fungus, known as C1. Dyadic is applying
its technologies to produce enzymes for use in converting various
agricultural products (e.g. corn) and waste products (e.g. switch
grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper, animal feed, alcohol, starch, and food
and beverage industries. Cautionary Statement for Forward-Looking
Statements Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements
involve risks and uncertainties that could cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. For a discussion of
these risks and uncertainties, please see our filings from time to
time with the Securities and Exchange Commission, which are
available free of charge on the SEC's web site at
http://www.sec.gov, including our Annual Report on Form 10-KSB for
the year ended December 31, 2005, and our subsequent filings with
the SEC. Except as required by law, we expressly disclaim any
intent or obligation to update any forward-looking statements.
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Dyadic International (American Stock Exchange): 0 recent articles
Plus d'articles sur Dyadic International, Inc.